2026³â 06¿ù 22ÀÏ ¿ù¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Parse Biosciences Announces Evercode TCR and Gene Capture

New immune profiling and enrichment capabilities expand applications and facilitate scalability
´º½ºÀÏÀÚ: 2023-02-08

HOLLYWOOD, FLA.-- February 08, 2023 -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Parse Biosciences portfolio to address higher scale and immune profiling applications.

Evercode TCR provides researchers the ability to profile T cell receptors (TCR) together with whole transcriptomes in single cells at scale. The diversity of possible TCRs in the immune repertoire is enormous, yet the low throughput of existing tools have limited the ability to capture this complexity at high resolution. Evercode TCR will enable researchers to measure whole transcriptomes and paired TCR sequences - both alpha and beta chains - in up to 1 million cells. Combining TCR sequences with gene expression at this scale makes it possible to track TCR clonotypes across different T cell subtypes and activation states to understand the immune repertoire at exceptional resolution.

Parse also announced the launch of Gene Capture, a solution to reduce sequencing needs for larger studies. Gene Capture focuses sequencing on the most relevant genes, making it possible to efficiently scale projects to millions of cells and hundreds of samples. The solution allows researchers to enrich for 100s-1000s of genes, requiring 10 times less sequencing. Researchers can order a predesigned panel of approximately 1,000 genes relevant to immunology, the Immune1000, or design a panel unique to their needs.

“Increasingly, we see the need to support larger single cell RNA sequencing studies. Biology is complex and requires robust studies across multiple samples, timepoints, and many individual cells to fully capture this complexity,” notes Parse co-founder and CEO Alex Rosenberg, Ph.D. “Parse’s technology has already brought unprecedented scale to the market, and these new tools will expand these capabilities, unlocking new applications in both the research and translational space.”

Charles Roco, Ph.D., Parse co-founder and CTO, will present on the capabilities of Parse’s Evercode TCR and Gene Capture products at the AGBT General Meeting this week at his session, “Broadening Access to Scalable Single Cell Sequencing,” on Wednesday, February 8 at 3:35 pm in the Grand Ballroom.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Telehouse Canada Undergoes Major Infrastructure Upgrade to Scale AI-Driven Organizations
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI
Boomi and Red Hat Collaborate on Production-Ready Agentic AI
Medisca and dsm-firmenich Partner to Expand Access to Pharma-Grade Vitamin APIs in U.S. Compounding Market
US Smartphone Market Declined 3% in 1Q26 Amid Pricing Pressure and Carrier Subsidy Shifts
Stabilizing Grids and Cutting Costs in Half: Europe Is Banking on Grid-Relevant Storage Systems

 

Celonis Launches Context Model to Eliminate AI Blind Spots, to Acquire...
Lenovo Named Leader and Star Performer in Mid-Market Digital Workplace...
Game Changer: How LG¡¯s Ultra-Large AI TVs Transform the Sports-Viewin...
SLB Industrializes AI for the Energy Industry with NVIDIA
Gradiant Delivers HyperSolved, Its AI Data Center Solution, to Leading...
NetApp, Red Hat Partner to Advance Data Protection and Scale for OpenS...
Cognite Flows¢â: Fully Integrated AI-Native Industrial Experience Driv...

 


°øÁö»çÇ×
¹Ìµð¾î¿Í M• Mediaour ØÚ体ä² ØÚô÷ä² ¿¥¿À MO ØÚä²
¾Ë¸®¾Ë A⋮⋮⋮ Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
À£ÇÁ·Ò W⋮⋮⋮ Welfrom 卫ÜØ êÛÝ£
¹ÙÀÌ¿ÀÀÌ´Ï B⋮ BIOINI ù±药研 ¹ÙÀÌ¿ÀÀÌ´Ï·¦ BIOINILAB ...
º£³×ÀÍ ¡Õ Beneik 宝Ò¬ìÌ, À̺ñÁî eBizh æ¶币òª EZ æ¶òª
¿¡³ÊÀÌÀ¯ ¡Õ¡Õ EnerEU 额Òö äþÒö
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¾Ë¸®À¯ºñ ^v Alliuv ä¹备 AV ä¹êó备, ¾Ë¶ã =^= Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º ¡ÕC À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò ^ Alfrom ä¹尔ÜØ ä¹ì³ÜØ, ¿ÃÇÁ·Ò A⋮⋮ Allfrom &...

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..